DelveInsight’s, “Mesothelioma Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Mesothelioma pipeline landscape. It covers the pipeline drug profiles, including Mesothelioma clinical trial and nonclinical stage products. It also covers the Mesothelioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Mesothelioma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Mesothelioma clinical trials studies, Mesothelioma NDA approvals (if any), and product development activities comprising the technology, Mesothelioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Mesothelioma Pipeline Report

 

• DelveInsight’s Mesothelioma Pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Mesothelioma treatment.

 

• The leading Mesothelioma Companies includes Kissei Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, Oncovir, Inc., Sumitomo Pharma Oncology, Bayer, Trizell Ltd, Hutchison Medipharma Limited, Targovax, Polaris Group, Epizyme, Inc., Sanofi, AstraZeneca, Ascentage Pharma Group Inc., Shionogi, Eli Lilly and Company, Incyte Corporation, GlaxoSmithKline, Constellation Pharmaceuticals, Tmunity Therapeutics, Xencor, Inc., NGM Biopharmaceuticals, Inc, Inhibrx, Inc., VM Oncology, LLC, SOTIO Biotech AG, Atara Biotherapeutics, and others.

 

• Promising Mesothelioma Pipeline Therapies includes Nivolumab, Ipilimumab, Pemetrexed, MTG201, THOR-707, Cisplatin, ZD1839, Anetumab ravtansine (BAY94-9343), Vinorelbine, YS110, Gemcitabine, NGR-hTNF, and others.

 

• The Mesothelioma companies and academics are working to assess challenges and seek opportunities that could influence Mesothelioma R&D. The Mesothelioma pipeline therapies under development are focused on novel approaches to treat/improve Mesothelioma.

 

To explore more information on the latest breakthroughs in the Mesothelioma Pipeline treatment landscape of the report, click here @ Mesothelioma Pipeline Outlook

 

Mesothelioma Overview

Mesothelioma is a cancer caused by asbestos. It most commonly occurs in the linings of the lungs or the abdomen. The average life expectancy is 18 – 31 months after diagnosis, but prognosis may improve with treatment. Symptoms can include chest pain, shortness of breath and general fatigue. Any amount of asbestos exposure can cause mesothelioma. However, certain occupations may experience higher rates of exposure. There are four main types of mesothelioma based on tumor location. The most common type is malignant pleural mesothelioma. After recognizing symptoms, doctors will perform a variety of tests and procedures to confirm a mesothelioma diagnosis. Biopsies are the only way to definitively diagnose mesothelioma Standard treatments for mesothelioma include surgery, chemotherapy and radiation therapy. The most common option is a multimodal approach, which combines two or more standard treatment options.

 

Mesothelioma Emerging Drugs Profile

 

• MesoPher: Amphera

MesoPher, a personalised immuno-oncology cell therapy, is comprised of autologous dendritic cells loaded with PheraLys, Amphera’s proprietary allogeneic lysate of mesothelioma cell lines. PheraLys, first developed for mesothelioma, contains a broad-spectrum of tumour-associated antigens, many of which are present in pancreatic cancer and other cancers. MesoPher is currently in a pivotal phase II/III study to treat Mesothelioma.

 

• Durvalumab: AstraZeneca

Durvalumab is an antibody (a type of human protein) that works by blocking a body substance called Programmed Death-Ligand 1 (PD-L1). Blocking PD-L1 helps the body’s immune system attack cancer cells. Research has shown that durvalumab can slow tumor growth and shrink tumors in some people with cancer. Previous studies of combining durvalumab and chemotherapy showed that this combination is active in advanced mesothelioma. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Advanced Pleural Mesothelioma.

 

For further information, refer to the detailed Mesothelioma Unmet Needs, Mesothelioma Market Drivers, and Mesothelioma Market Barriers, click here for Mesothelioma Ongoing Clinical Trial Analysis

 

Mesothelioma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Mesothelioma. The companies which have their Mesothelioma drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

 

Mesothelioma Pipeline: Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Request a sample and discover the recent advances in Mesothelioma Ongoing Clinical Trial Analysis and Medications, click here @ Mesothelioma Treatment Landscape

 

Scope of the Mesothelioma Pipeline Report

 

• Coverage- Global

 

• Mesothelioma Companies- Kissei Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, Oncovir, Inc., Sumitomo Pharma Oncology, Bayer, Trizell Ltd, Hutchison Medipharma Limited, Targovax, Polaris Group, Epizyme, Inc., Sanofi, AstraZeneca, Ascentage Pharma Group Inc., Shionogi, Eli Lilly and Company, Incyte Corporation, GlaxoSmithKline, Constellation Pharmaceuticals, Tmunity Therapeutics, Xencor, Inc., NGM Biopharmaceuticals, Inc, Inhibrx, Inc., VM Oncology, LLC, SOTIO Biotech AG, Atara Biotherapeutics, and others

 

• Mesothelioma Pipeline Therapies- Nivolumab, Ipilimumab, Pemetrexed, MTG201, THOR-707, Cisplatin, ZD1839, Anetumab ravtansine (BAY94-9343), Vinorelbine, YS110, Gemcitabine, NGR-hTNF, and others.

 

• Mesothelioma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Mesothelioma Market Drivers and Mesothelioma Market Barriers, click here @ Mesothelioma Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Mesothelioma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Mesothelioma – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Mesothelioma Collaboration Deals
9. Late Stage Products (Phase III)
10. Durvalumab: AstraZeneca
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. TRC102: TRACON Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. SG001: CSPC ZhongQi Pharmaceutical Technology
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Mesothelioma Key Companies
23. Mesothelioma Key Products
24. Mesothelioma- Unmet Needs
25. Mesothelioma- Market Drivers and Barriers
26. Mesothelioma- Future Perspectives and Conclusion
27. Mesothelioma Analyst Views
28. Mesothelioma Key Companies
29. Appendix

 

Got Queries? Find out the related information on Mesothelioma Mergers and acquisitions, Mesothelioma Licensing Activities @ Mesothelioma Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services